Abstract 359P
Background
Although engaging in exercise after breast cancer surgery (BCS) has been shown to facilitate faster recovery, factors influencing exercise participation during the early recovery phase remain unclear in breast cancer patients. Therefore, this study aimed to explore the perceptions, attitudes, and barriers to exercise in breast cancer patients immediately after surgery and up to 4 weeks post-surgery.
Methods
A descriptive qualitative research method was employed to investigate this topic. A purposive sample of 33 breast cancer patients was selected, and each participant was interviewed three times over a one-month period after surgery.
Results
We found physical constraints and psychological resistance were identified as barriers to exercise. Postoperative physical symptoms (pain, range of motion, lack of fitness, and seroma) and surgical drains were identified as physical constraints. Participants also faced psychological resistance such as concerns about side effects, lack of willpower, and fear of pain. Furthermore, a lack of trustworthy information regarding the timing of exercise initiation and proper types of exercise after surgery was identified as a psychological resistance. Table: 359P
Themes, codes, and categories from the interviews
Categories | %(n) | Codes | %(n) | Theme | %(n) |
Physical constraints | 100% (33) | Postoperative physical symptoms | 100% (33) | Pain at the surgery site | 87.9% (29) |
Limited range of motion | 66.6% (22) | ||||
Lack of fitness | 33.3% (11) | ||||
Seroma | 12.2% (4) | ||||
Operation derived condition | 45.4% (15) | Drain | 45.5% (15) | ||
Psychological resistance | 48.5% (16) | Perception and attitude | 54.5% (18) | Concerns about side effects | 42.4% (13) |
Lack of willpower | 15.2% (5) | ||||
Fear of pain | 15.2% (5) | ||||
Concerns due to lack of trustworthy exercise information | 54.5% (18) | Concerns regarding the exercise timing being inappropriate | 42.4% (14) | ||
Discouragement from others | 18.2% (6) |
Conclusions
The identified barriers, both physical and psychological, should be taken into consideration when developing strategies to motivate and support patients in engaging in exercise. The identified barriers, both physical and psychological, should be taken into consideration when developing strategies to motivate and support patients in engaging in exercise.
Clinical trial identification
This study involves human participants and was approved by the Institutional Review Board of Severance Hospital (IRB No. 4-2018-1094).
Editorial acknowledgement
This work was supported by the National Research Foundation of Korea grant number NRF-2017S1A5A2A01024689, NRF-2021S1A5B5A16077404, the National R&D Programme for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA21C0067000021) and the Yonsei Signature Research Cluster Programme 2021220009.
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Research Foundation of Korea grant number NRF-2017S1A5A2A01024689, NRF-2021S1A5B5A16077404, the National R&D Programme for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA21C0067000021) and the Yonsei Signature Research Cluster Programme 2021220009.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
393P - Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)
Presenter: Kevin Kalinsky
Session: Poster session 03
394P - CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
Presenter: Francesco Pantano
Session: Poster session 03
395P - Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Presenter: Kyung Jung
Session: Poster session 03
396P - Real-world treatment and survival outcomes in previously untreated patients with metastatic triple-negative breast cancer (mTNBC) in the United States (US)
Presenter: Kevin Punie
Session: Poster session 03
398P - A phase Ib/II study of IN10018/FAKi in combination with pegylated liposomal doxorubicin (PLD) and toripalimab in metastatic triple-negative breast cancer (TNBC): IN10018-010
Presenter: Xichun Hu
Session: Poster session 03
399P - Results from a first-in-human phase Ia/b study of LX-039, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal patients with ER+, HER2- advanced breast cancer (ABC)
Presenter: weina shen
Session: Poster session 03
400P - The impact of CDK4/6 inhibitors on bone health: An Italian real-world experience
Presenter: Roberta Scafetta
Session: Poster session 03
401P - Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer with brain metastasis (UTOBIA-BM): A prospective, single-arm, phase II trial
Presenter: Yehui Shi
Session: Poster session 03
402P - First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study
Presenter: Hamdy Azim
Session: Poster session 03